Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume

Summary

This multicentre, open-label, single-arm Study is to evaluate the effect of Rosuvastatin 20 mg 76 weeks on coronary atherosclerosis plaque versus baseline in Chinese coronary heart disease (CHD) patients with hyperlipidemia by measuring the plaque volume using a 64 slice spiral CT. Effect on blood lipids, hsCRP and Carotid intima-media thickness (CIMT) is also evaluated.

Timeline

Start

2011-03

Primary completion

2013-04

Completion

2013-04

Drugs

Indications